WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406651
Description: DW532 is one of simplified analogues of hematoxylin that has shown broad-spectrum inhibition on tyrosine kinases and in vitro anti-cancer activities. DW532 inhibited EGFR and VEGFR2 in vitro kinase activity (the IC50 values were 4.9 and 5.5 μmol/L, respectively), and suppressed their downstream signaling. DW532 dose-dependently inhibited tubulin polymerization via direct binding to tubulin, thus disrupting the mitotic spindle assembly and leading to abnormal cell division. In a panel of human cancer cells, DW532 (1 and 10 μmol/L) induced G2/M phase arrest and cell apoptosis, which subsequently resulted in cytotoxicity. Knockdown of BubR1 or Mps1, the two core proteins of the spindle assembly checkpoint dramatically decreased DW532-induced cell cycle arrest in MDA-MB-468 cells. Moreover, treatment with DW532 potently and dose-dependently suppressed angiogenesis in vitro and in vivo. ( Acta Pharmacol Sin. 2014 Jul;35(7):916-28.)
MedKoo Cat#: 406651
Chemical Formula: C16H12O6
Exact Mass: 300.0634
Molecular Weight: 300.266
Elemental Analysis: C, 64.00; H, 4.03; O, 31.97
Synonym: DW532; DW-532; DW 532.
IUPAC/Chemical Name: 7,8-dihydroxy-4-(3-hydroxy-4-methoxyphenyl)-2H-chromen-2-one
InChi Key: IHPLZLMGSYGDMA-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H12O6/c1-21-13-5-2-8(6-12(13)18)10-7-14(19)22-16-9(10)3-4-11(17)15(16)20/h2-7,17-18,20H,1H3
SMILES Code: O=C1C=C(C2=CC=C(OC)C(O)=C2)C3=C(O1)C(O)=C(O)C=C3
1: Peng T, Wu JR, Tong LJ, Li MY, Chen F, Leng YX, Qu R, Han K, Su Y, Chen Y, Duan WH, Xie H, Ding J. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin. Acta Pharmacol Sin. 2014 Jul;35(7):916-28. doi: 10.1038/aps.2014.33. Epub 2014 May 26. PubMed PMID: 24858311; PubMed Central PMCID: PMC4088284.